|
[1]
|
World Health Organization (2024) Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection. World Health Organization.
|
|
[2]
|
尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版) [J]. 实用肝脏病杂志, 2023, 26(3): 457-478.
|
|
[3]
|
Terrault, N.A., Lok, A.S.F., McMahon, B.J., Chang, K., Hwang, J.P., Jonas, M.M., et al. (2018) Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 67, 1560-1599. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H.L.A., Papatheodoridis, G., et al. (2017) EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Zhang, Q., Peng, H., Liu, X., Wang, H., Du, J., Luo, X., et al. (2021) Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease. Journal of Clinical and Translational Hepatology, 9, 850-859. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Kim, J.H., Sinn, D.H., Kang, W., Gwak, G., Paik, Y., Choi, M.S., et al. (2016) Low‐Level Viremia and the Increased Risk of Hepatocellular Carcinoma in Patients Receiving Entecavir Treatment. Hepatology, 66, 335-343. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Sarin, S.K., Kumar, M., Lau, G.K., Abbas, Z., Chan, H.L.Y., Chen, C.J., et al. (2015) Asian-Pacific Clinical Practice Guidelines on the Management of Hepatitis B: A 2015 Update. Hepatology International, 10, 1-98. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021, 37(6): 1268-1274.
|
|
[9]
|
Sun, Y., Wu, X., Zhou, J., Meng, T., Wang, B., Chen, S., et al. (2020) Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression during Therapy. Clinical Gastroenterology and Hepatology, 18, 2582-2591.E6. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Sinn, D.H., Lee, J., Goo, J., Kim, K., Gwak, G., Paik, Y., et al. (2015) Hepatocellular Carcinoma Risk in Chronic Hepatitis B Virus-Infected Compensated Cirrhosis Patients with Low Viral Load. Hepatology, 62, 694-701. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Kim, T., Sinn, D.H., Kang, W., Gwak, G., Paik, Y., Choi, M.S., et al. (2019) Hepatitis B Virus DNA Levels and Overall Survival in Hepatitis B‐Related Hepatocellular Carcinoma Patients with Low‐Level Viremia. Journal of Gastroenterology and Hepatology, 34, 2028-2035. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Chen, Y., Yang, C., Kuo, H., Sheu, M., Feng, I., Liu, C., et al. (2024) Risk Factors and Nomogram Model for Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients with Low-Level Viremia. International Journal of Medical Sciences, 21, 1661-1671. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
邹铭南, 蔡大川, 任红. 慢性乙肝抗病毒治疗过程中低病毒血症对病毒学与肝脏获益的影响[J]. 川北医学院学报, 2021, 36(9): 1117-1123.
|
|
[14]
|
李光海. NAs治疗慢乙肝低病毒血症危险因素分析及治疗策略选择[D]: [硕士学位论文]. 海口: 海南医学院, 2023.
|
|
[15]
|
Yoo, E. and Cho, H. (2017) Clinical Response to Long-Term Tenofovir Monotherapy in Korean Chronic Hepatitis B Patients. Clinica Chimica Acta, 471, 308-313. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
刘丽萍. 恩替卡韦经治后低病毒血症的慢性乙型肝炎患者序贯联合富马酸丙酚替诺福韦治疗的疗效及影响因素分析[D]: [硕士学位论文]. 南昌: 南昌大学, 2024.
|
|
[17]
|
冉书容, 刘洋, 雷兰. 恩替卡韦经治的慢性乙型肝炎患者发生低病毒血症危险因素及转换TAF治疗疗效研究[J]. 实用肝脏病杂志, 2024, 27(5): 681-684.
|
|
[18]
|
Han, J., Guo, Y., Zhang, X., Zhang, Y., Sun, J., He, J., et al. (2023) Prevalence and Associated Factors of Low-Level Viremia in Chronic Hepatitis B Patients after Long-Term Therapy with Nucleos(t)ide Analogs. The Turkish Journal of Gastroenterology, 34, 53-61. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Koumbi, L. (2015) Current and Future Antiviral Drug Therapies of Hepatitis B Chronic Infection. World Journal of Hepatology, 7, Article 1030. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Allweiss, L., Volz, T., Giersch, K., Kah, J., Raffa, G., Petersen, J., et al. (2017) Proliferation of Primary Human Hepatocytes and Prevention of Hepatitis B Virus Reinfection Efficiently Deplete Nuclear Cccdna in vivo. Gut, 67, 542-552. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Zhang, Q., Cai, D., Hu, P. and Ren, H. (2021) Low-Level Viremia in Nucleoside Analog-Treated Chronic Hepatitis B Patients. Chinese Medical Journal, 134, 2810-2817. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Yin, G., Li, J., Zhong, B., Yang, Y. and Wang, M. (2021) New Therapeutic Options for Persistent Low-Level Viremia in Patients with Chronic Hepatitis B Virus Infection: Increase of Entecavir Dosage. World Journal of Gastroenterology, 27, 666-676. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Ogawa, E., Nomura, H., Nakamuta, M., Furusyo, N., Koyanagi, T., Dohmen, K., et al. (2020) Tenofovir Alafenamide after Switching from Entecavir or Nucleos(t)ide Combination Therapy for Patients with Chronic Hepatitis B. Liver International, 40, 1578-1589. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Li, Z., Li, L., Niu, X., Chen, S., Fu, Y., Wang, C., et al. (2021) Switching from Entecavir to Tenofovir Alafenamide for Chronic Hepatitis B Patients with Low‐Level Viraemia. Liver International, 41, 1254-1264. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
谢露, 刘亚楠, 刘光伟, 等. 经治慢性乙型肝炎患者低病毒血症发生率和影响因素的Meta分析[J]. 临床肝胆病杂志, 2024, 40(7): 1334-1342.
|